LLY Stock Recent News

Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.

These innovative drugmakers have potential catalysts ahead.

Eli Lilly is investing billions into new research and manufacturing capabilities.

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

Lilly is staying ahead of the technology curve instead of falling behind.

Results from Lilly's "Urgent Conversations" survey reinforce the work by the Crohn's & Colitis Foundation of America, including the "We Can't Wait" mobile bathroom finder app INDIANAPOLIS , Oct. 16, 2024 /PRNewswire/ -- Results from the national "Urgent Conversations" survey, announced today by Eli Lilly and Company (NYSE: LLY), found that over half (60%) of the general population struggle to find a public restroom, a challenge that is even more pronounced (84%) for people with ulcerative colitis (UC).1 This survey, of 1,800 U.S. adults, including 200 people with moderately to severely active UC, assessed the availability and accessibility of public restrooms. UC is a chronic, inflammatory disease that affects the colon and rectum of the gastrointestinal tract and is associated with increased stool frequency, rectal bleeding and bowel urgency.

These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.

Lilly has invested billions of dollars to ramp up production capacity.

The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide while reconsidering the drug's supply status.